Active, not recruitingPHASE1, PHASE2NCT04364178
Viral Specific T-Lymphocytes to Treat Adenovirus or CMV
Studying Adenovirus infection in immunocompromised patients
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Jessie L. Alexander
- Principal Investigator
- Jessie Alexander, MDStanford University
- Intervention
- Adenovirus Specific T- Lymphocytes(biological)
- Enrollment
- 25 enrolled
- Eligibility
- 65 years · All sexes
- Timeline
- 2020 – 2032
Study locations (2)
- Jessie Alexander, Palo Alto, California, United States
- Lucile Packard Children's Hospital, Palo Alto, California, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04364178 on ClinicalTrials.govOther trials for Adenovirus infection in immunocompromised patients
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05101213Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer PatientsM.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT03425526Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related DiseaseM.D. Anderson Cancer Center
See all trials for Adenovirus infection in immunocompromised patients →